FDA Grants Fast Track Designation to CAN-3110 for Recurrent High-Grade Glioma

CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.

Related Keywords

Massachusetts ,United States ,Boston ,Antonio Chiocca ,Harvard Medical School ,Department Of Neurosurgery At Brigham ,Peter Tak ,Candel Therapeutics ,Can 3110 ,Adult Patients With Recurrent High Grade Glioma ,Paul Peter Tak ,D ,Phd ,Medsci ,Brigham And Womens Hospital ,